Acacia Pharma Raises £15M in Series B Financing

Acacia Pharma, a Cambridge, UK-based pharmaceutical company specializing in the development of drugs for supportive care, raised £15m (approximately $23.5m) in Series B financing.

The round was led by Fidelity Biosciences and Novo A/S, with participation from current investors Gilde Healthcare and Lundbeckfond Ventures. In conjunction with the funding, Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo A/S joined the Board of Acacia Pharma as Non-executive Directors.

The company intends to use the funds to complete Phase III development of APD421 for the prevention of post-operative nausea & vomiting (PONV) and Phase II development of APD403 for the prevention of chemotherapy induced nausea & vomiting (CINV) and develop the commercial presentation of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.

Acacia is led by Dr Julian Gilbert, CEO.



Join the discussion